295 related articles for article (PubMed ID: 18453363)
1. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
Falk JA; Minai OA; Mosenifar Z
Proc Am Thorac Soc; 2008 May; 5(4):506-12. PubMed ID: 18453363
[TBL] [Abstract][Full Text] [Related]
2. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
Yang IA; Fong KM; Sim EH; Black PN; Lasserson TJ
Cochrane Database Syst Rev; 2007 Apr; (2):CD002991. PubMed ID: 17443520
[TBL] [Abstract][Full Text] [Related]
3. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
4. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
5. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
6. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
7. Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.
Melani AS; Croce S; Fabbri G; Messina M; Bargagli E
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397432
[TBL] [Abstract][Full Text] [Related]
8. Inhaled corticosteroids in COPD: a controversy.
Barnes PJ
Respiration; 2010; 80(2):89-95. PubMed ID: 20501985
[TBL] [Abstract][Full Text] [Related]
9. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
10. Inhaled corticosteroids in chronic obstructive pulmonary disease.
Suissa S; McGhan R; Niewoehner D; Make B
Proc Am Thorac Soc; 2007 Oct; 4(7):535-42. PubMed ID: 17878466
[TBL] [Abstract][Full Text] [Related]
11. The risk/benefit of inhaled corticosteroids in chronic obstructive pulmonary disease.
Bonay M; Bancal C; Crestani B
Expert Opin Drug Saf; 2005 Mar; 4(2):251-71. PubMed ID: 15794718
[TBL] [Abstract][Full Text] [Related]
12. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease.
Nannini LJ; Cates CJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2007 Oct; (4):CD006829. PubMed ID: 17943918
[TBL] [Abstract][Full Text] [Related]
13. A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management.
Micheletto C; Braido F; Contoli M; Di Marco F; Santus P
Int J Chron Obstruct Pulmon Dis; 2019; 14():2185-2193. PubMed ID: 31576115
[TBL] [Abstract][Full Text] [Related]
14. Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.
Bonay M; Bancal C; Crestani B
Drug Saf; 2002; 25(1):57-71. PubMed ID: 11820912
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety Comparison for Systemic Corticosteroid Therapy With and Without Inhaled Corticosteroids for COPD Exacerbation Management.
Pearce JA; Shiltz DL; Ding Q
Ann Pharmacother; 2018 Nov; 52(11):1070-1077. PubMed ID: 29783858
[TBL] [Abstract][Full Text] [Related]
16. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Tan DJ; White CJ; Wood-Baker R
Cochrane Database Syst Rev; 2014 Dec; (12):CD006897. PubMed ID: 25491891
[TBL] [Abstract][Full Text] [Related]
17. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
[TBL] [Abstract][Full Text] [Related]
18. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis.
Puhan MA; Bachmann LM; Kleijnen J; Ter Riet G; Kessels AG
BMC Med; 2009 Jan; 7():2. PubMed ID: 19144173
[TBL] [Abstract][Full Text] [Related]
19. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease.
Glaab T; Taube C
Pulm Pharmacol Ther; 2011 Feb; 24(1):15-22. PubMed ID: 20816832
[TBL] [Abstract][Full Text] [Related]
20. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
